Decoding Covaxin's Final Phase 3 Trial Data With Dr Shahid Jameel | The Quint

Bharat Biotech has released the final phase 3 trial data for its covid-19 vaccine, Covaxin. According to the preprint results, Covaxin has an overall efficacy of 77.8 percent. What does the data mean? Does this mean Covaxin could get WHO approval soon? How does Covaxin compare to Covishield? FIT speaks to Dr Shahid Jameel. #Covaxin #CovidVaccine #BharatBiotech #Interview

0:19 Why is the final efficacy lower than the efficacy shown in interim results?
2:35 What is 'peer review'?
3:47 Can this data be taken at face value?
3:51 Why is peer review important?
4:15 How was Covaxin's efficacy against the delta variant determined?
5:42 Could Covaxin get a WHO approval soon?
6:35 How does Covaxin compare to other Covid-19 vaccines?

Support The Quint's independent journalism. Become a member now: https://bit.ly/2KzaT9R
__________________
Check out The Quint for more news: https://www.thequint.com
The Quint in Hindi: https://hindi.thequint.com
For more videos, subscribe to our YouTube channel: http://bit.ly/2aIcith

You can also follow The Quint here:
Facebook: http://bit.ly/1RXYIg5
Twitter: http://bit.ly/1tjFuxI
Instagram: http://bit.ly/1Piyc18

Видео Decoding Covaxin's Final Phase 3 Trial Data With Dr Shahid Jameel | The Quint канала The Quint